id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-327545-y3vejwtr	Shannon, Vickie R.	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity	2020-09-03		.txt	text/plain	5718	267	33	Management principles for ICI-related lung injury, including current consensus on steroid refractory pneumonitis and the use of other immune modulating agents in this setting are also highlighted. Fatal IrAEs associated with severe graft versus host disease following hematopoietic stem cell transplantation in patients with hematologic malignancies who had been previously exposed to ICI therapies have raised concerns regarding the use of ICIs in this setting [39, 40] . The prevalence of pneumonitis will undoubtedly continue to grow in Fig. 5 Approach to management of ICI-related interstitial lung disease Support Care Cancer parallel with better recognition of this clinical entity coupled with the expanding indication of ICI therapies to other tumor types and the addition of these agents to complex treatment strategies that carry an additional toxicity risk. The relative risk and incidence of immune checkpoint inhibitors related pneumonitis in patients with advanced cancer: a meta-analysis	./cache/cord-327545-y3vejwtr.txt	./txt/cord-327545-y3vejwtr.txt